Daniel Lavall

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary

Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside

Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association

Acute kidney injury

Recent advances in the molecular pathophysiology of atrial fibrillation

Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection

Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men’s Issue?

Regulatory networks defining EMT during cancer initiation and progression

Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis

HIF-1α is required for development of the sympathetic nervous system

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

2020 International Society of Hypertension Global Hypertension Practice Guidelines

Lysyl Oxidase: From Basic Science to Future Cancer Treatment

Mineralocorticoid Receptor and Cardiovascular Disease

The Mineralocorticoid Receptor Promotes Fibrotic Remodeling in Atrial Fibrillation

True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis

Rac1-Induced Connective Tissue Growth Factor Regulates Connexin 43 and N-Cadherin Expression in Atrial Fibrillation

Rac1 GTPase regulates 11β hydroxysteroid dehydrogenase type 2 and fibrotic remodeling

Increased lysyl oxidase expression and collagen cross-linking during atrial fibrillation